Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab Before and After CAR T-Cell Therapy in R/R DLBCL
NCT06854159Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Aug 2025
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odronextamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of California, Davis. Primary endpoint: Complete Response Rate at 15 weeks. Started Aug 2025; status: recruiting.
02
Drugs
odronextamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06854159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854159.